Taking the driving seat on pharma and life science investments
Investments in the life science and pharmaceutical industries are a different ballgame.
A Practical Checklist of Things to Avoid with New Launches of Prescription-Only Medicines in Singapore
Pharmaceutical companies that plan launches of prescription-only medicines need to be aware: there are regulatory matters in Singapore things which can interrupt your launch if they’re not sufficiently attended to.
“Earned Media” – Legitimate Publicity for Medical Products or Disguised Product Promotion?
It should come as no surprise that the marketing of pharmaceutical products is regulated – and that even advertisements of such products are regulated.
The Thaler decision – AI Need Not Apply … At least Not yet….
The UK Supreme Court held, on 20 December 2023, that an AI system could NOT be an inventor for two UK Patent applications.
Black Cats & Generative A.I. – How LLMs are looked at from a Copyright perspective
Developers and users of Generative A.I. (“Gen A.I.”) can find themselves having to navigate copyright challenges but to do so requires some understanding of both how a Gen A.I. model manipulates copyright works as part of its training and development and how copyright law might apply to such use.
A.I. & Copyright – Did Singapore’s Copyright Act 2021 solve copyright problems in the Training of A.I.?
When Artificial Intelligence models are trained against data, the potential for copyright infringement exists under the laws of some, if not most, countries. Did Singapore’s Copyright Act 2021 solve this problem? This article explores what Singapore’s changes to its laws mean. By Jeffrey Lim